Vanqua Bio
Manufacturing · Illinois, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2430 N Halsted St Ste 110, Chicago, Illi...Phone Number
(224) 517-1598Website
www.vanquabio.comRevenue
$5.7 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Vanqua Bio
Vanqua Bio is a biopharmaceutical company focused on discovering and developing next-generation medicines for neurodegenerative diseases.Explore more
Vanqua Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Vanqua Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Vanqua Bio
Product Launch: Get notified when Vanqua Bio launches new products
Funding: Get notified immidiatlly once Vanqua Bio has new funding data
Vanqua Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Vanqua Bio recently announced quarterly report
Check out if Vanqua Bio is spiking on competitors!
Click to see if Vanqua Bio had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Vanqua Bio has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Vanqua Bio
Find 2 more new buyers
Compare Similar Companies to Vanqua Bio
Compare insights from companies similar to Vanqua Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Vanqua Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Vanqua Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Vanqua Bio.
Vanqua Bio financials insights
Gather financial insights about Vanqua Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series B
$85M
Vanqua Bio Tech Stack
A closer look at the technologies used by Vanqua Bio
See more technologies
Most Recent Scoops
Project
Product Development, Research & Development, Intellectual Property, Legal Affairs, Medical Research, Pharmaceuticals
New Hire
Executive Move
Executive Moves, New Hire
Lateral Move
Executive Move
Executive Moves, Lateral Move
New Hire
Executive Move
Executive Moves, New Hire
Lateral Move
Executive Move
Executive Moves, Lateral Move
Vanqua Bio News & Media
Vanqua Bio to Present at the AD/PD™ 2026 International Conference
CHICAGO, March 12, 2026 (GLOBE NEWSWIRE) -- Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present at AD/PDTM 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, taking place in Copenhagen, Denmark on March 17-21.Biogen licenses a possible immune drug from OrbiMed-backed biotech | BioPharma Dive
The preclinical drug from Vanqua Bio is designed to inhibit “C5aR1,” a part of the immune system that regulates inflammation.Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
CAMBRIDGE, Mass. and CHICAGO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Vanqua Bio today announced a license agreement granting Biogen exclusive worldwide rights to Vanqua’s preclinical, oral C5aR1 antagonist. This agreement strengthens Biogen’s immunology strategy by advancing a proven immune mechanism with the potential to address a broad range of inflammatory disorders with high unmet need.Vanqua Bio Highlights Positive Interim Data from its Ongoing Phase 1b Clinical Trial of VQ-101, an Allosteric Activator of GCase for the Treatment of GBA-Parkinson’s and Related Disorders, at The International Congress of Parkinson’s Disease and Movement Disorders®
CHICAGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Vanqua Bio, a clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation medicines for the treatment of neurodegenerative diseases, announced positive interim results from the Phase 1b portion of its clinical trial of VQ-101, an orally administered, fully brain-penetrant, allosteric activator of GCase. The Phase 1b portion of the study is evaluating safety, pharmacokinetics, and pharmacodynamics across multiple asce
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Vanqua Bio
Sign Up For FreeTo access detailed company insights
Vanqua Bio is a biopharmaceutical company focused on discovering and developing next-generation medicines for neurodegenerative diseases.... Read More
